Mrs. Pilgaonkar has over 42 years’ experience in the pharmaceutical industry, conceptualizing, establishing and spearheading research groups of qualified scientists in leading Indian and multinational organizations. Mrs. Pilgaonkar has led R&D teams at Burroughs Wellcome (now GSK), Ciba Geigy (now Novartis) and Sun Pharma. As VP - R&D, Sun Pharma, she played a pivotal role in the acquisition of Caraco Pharmaceuticals and turnaround of the generic business. She has numerous patents and publications to her credit and has developed platform technologies for various applications in the Pharmaceutical Industry.
Mrs. Pilgaonkar graduated in Chemical Technology from University Institute of Chemical Technology (UICT) and in Chemistry from University of Mumbai.
Dr. Karajgi has overall technical experience of 25 years, of which the last 12 years have been in techno-commercial leadership roles, helping organizations achieve their goals. Dr. Karajgi leads technical development and manufacturing operations at Rubicon, as Rubicon ventures into various dosage forms, innovative platforms and multi-site operations. Dr. Karajgi’s core expertise is Formulation Development and Technical Services of all kinds of dosage forms across various pharmacological and therapeutic categories.
In his most recent assignments, Dr. Karajgi was Chief Scientific Officer at Wockhardt and President – R&D at Aurobindo Pharmaceuticals. Dr. Karajgi was also associated with Famycare Ltd., Able Labs USA, Trigen/ Cadista Labs USA, Sun Pharma/Caraco USA and Ranbaxy.
Dr. Karajgi has completed his M. Pharm (Pharmaceutics) and Ph.D. in Novel Drug Delivery Systems from University of Sagar.
Mr. Pilgaonkar has over 42 years of experience in technical operations and manufacturing valued added specialty pharmaceutical products. During his stint at Hoechst (Sanofi Aventis), he headed the inventory control function for Pharma and Agro Divisions in India and achieved high process excellence in streamlining inventory management systems for both the SBUs. He has technical operations experience spanning from fine chemicals to finished formulations. These diverse techno-commercial skill-sets acquired at Hoechst (Sanofi Aventis) spurred on his entrepreneurial venture: Galentic Pharma – a sterile products and specialty manufacturing unit which he successfully set up and operated as a Greenfield project.
Mr. Pilgaonkar graduated in Chemical Technology from University Institute of Chemical Technology (UICT) and in Chemistry from University of Mumbai.
Dr. Rao has over 50 years of pharmaceutical research experience coupled with regulatory expertise. He has numerous patents and publications in the area of drug delivery systems. Dr Rao had positions of responsibility at Wellcome Foundation (GlaxoSmithKline) at Kent (U.K.). He was also head of Product Development at Indian operations of Burroughs Wellcome (GlaxoSmithKline). During his stint at GlaxoSmithKline he was responsible for various NDA applications including Zovirax and novel liposomal formulations.
His most recent assignments included heading scientific affairs at Chauvin Pharmaceuticals Ltd (U.K.) and Smith and Nephew Pharmaceuticals Ltd (U.K.) He is widely regarded as an expert in developing complex dosage forms such as AMETOP®, NODS® (Novel Opthalmic Delivery System), MINIMS® format, development of an aqueous suspension formulation of acyclovir for the treatment of herpes simplex keratitis amongst many others.
Dr. Rao is a Fellow of the Royal Society of Chemistry and Member of the British Institute of Regulatory Affairs.
Parag is Vice President - Corporate Finance and Strategy at Rubicon Research Pvt. Ltd. and serves on the Board of Directors.
Parag has a prior experience in the venture capital and private equity domain and assisted several small and medium business enterprises in sourcing and evaluation of new partnership opportunities, conducting due-diligence for potential partnership opportunities and closing transactions. At Rubicon Parag is directly responsible for all corporate matters including growth strategy and investor relations.
Parag has completed his Bachelors in Commerce from Symbiosis International University in, followed by his Masters in Economics from Gokhale Institute of Politics and Economics. Parag became a CFA charter holder from the CFA Institute, USA in the year 2010.
Surabhi is responsible for Business Development & Licensing and Project Management.Surabhi has pioneered technology partnerships at Rubicon, and has till date inked several technology partnership deals with leading global organizations worldwide. This is in addition to executing numerous service contracts (both on the product development as well as on the supply chain side) with leading pharmaceutical companies. Surabhi has developed innovative methods for structuring the licensing deals in order to reach a win-win solution for both parties and has worked extensively with general counsels during negotiations. Surabhi has established robust project management practices which helps Rubicon deliver its projects on time.
Surabhi holds an MBA (Finance and Business Strategy) from Case Western University,Ohio, Masters in Economics from Gokhale Institute of Politics and Economics and Bachelors of Arts (Statistics and Economics) from St. Xavier’s College, Mumbai.